Product Center
Breaking through bottleneck technology, significant progress has been made in the research and development of new adjuvants
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-08-26
- Views:
(Summary description)On August 25th, the R&D team of Yither Biotech (Shanghai) Co., Ltd, a wholly-owned subsidiary of Ab&B Bio-Tech Co.,Ltd（Ab&B Bio）, made a breakthrough in the field of innovative adjuvant research and development. The research results were published online in the internationally renowned journal "Journal of Drug Delivery Science and Technology" under the title "Dual functional Emulsifier Based Nano Emulsification Adjuvant Effectively Enhanced Immunogenicity of Recombinant Respiratory Syncytial Virus Vaccine in Mice".
Breaking through bottleneck technology, significant progress has been made in the research and development of new adjuvants
(Summary description)On August 25th, the R&D team of Yither Biotech (Shanghai) Co., Ltd, a wholly-owned subsidiary of Ab&B Bio-Tech Co.,Ltd（Ab&B Bio）, made a breakthrough in the field of innovative adjuvant research and development. The research results were published online in the internationally renowned journal "Journal of Drug Delivery Science and Technology" under the title "Dual functional Emulsifier Based Nano Emulsification Adjuvant Effectively Enhanced Immunogenicity of Recombinant Respiratory Syncytial Virus Vaccine in Mice".
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-08-26 18:05
- Views:
On August 25th, the R&D team of Yither Biotech (Shanghai) Co., Ltd, a wholly-owned subsidiary of Ab&B Bio-Tech Co.,Ltd（Ab&B Bio）, made a breakthrough in the field of innovative adjuvant research and development. The research results were published online in the internationally renowned journal "Journal of Drug Delivery Science and Technology" under the title "Dual functional Emulsifier Based Nano Emulsification Adjuvant Effectively Enhanced Immunogenicity of Recombinant Respiratory Syncytial Virus Vaccine in Mice".
Subunit vaccines, genetically engineered vaccines, etc. usually require the addition of adjuvants to enhance their immunogenicity and activate effective immune responses. However, the number of components in a vaccine is not necessarily better, and adjuvants that combine delivery and immune stimulation functions are the most ideal. Therefore, the company's R&D team targeted different types of immune responses, combined with the structural characteristics of immune stimulators, while ensuring safety, and took the lead in using emulsifiers with immune stimulatory functions to develop efficient preparation processes and unique nanoemulsion adjuvants. The results of animal experiments show that the use of this adjuvant, combined with our self-developed recombinant protein antigen, can effectively stimulate the body's humoral and cellular immune abilities. Compared with MF59 and aluminum/CpG adjuvant systems, it exhibits significant advantages. At present, the adjuvant can achieve GMP production, and the invention patent for "a nanoemulsion adjuvant (application number 2023103883104)" based on the adjuvant application has also entered the substantive examination stage.
Yihui Biotechnology actively expands into the field of innovative adjuvants, focusing on the research and development of "nano adjuvant formulations, new immunostimulants, and composite adjuvant systems". Based on antigen characteristics, it develops its exclusive adjuvants and production processes, aiming to efficiently enhance the body's immune response, reduce the risk of adverse reactions, and reduce the amount of antigen used. The company is independently developing multiple adjuvants and gradually applying them to innovative products such as pneumococcal polysaccharide conjugate vaccines, recombinant herpes zoster vaccines, and recombinant respiratory syncytial virus vaccines, providing an "acceleration" for the company's innovative vaccine production.
Relevant information
-
The application for the marketing of trivalent influenza virus subunit vaccine has been accepted!Recently, Ab&B Bio-Tech Co.,Ltd（Ab&B Bio）has received acceptance from the Drug Evaluation Center (CDE) of the China National Medical Products Administration for its application to market the "6-35 month old trivalent influenza virus subunit vaccine" and the "3-year-old and above trivalent influenza virus subunit vaccine". This acceptance marks the final sprint stage of the first domestic full dose trivalent influenza virus subunit vaccine for people aged 6 months and above, which is about to be launched! - Breaking through bottleneck technology, significant progress has been made in the research and development of new adjuvants 08-26
- Obtained recognition as one of the first offshore innovation centers for enterprises in Taizhou 08-14
- Recombinant herpes zoster vaccine (CHO cells) IND application approved 08-13
- IND application for quadrivalent influenza virus subunit vaccine (adjuvant) approved 07-30
Have a project？Get a touch!
Caring for life, protecting health, and making global technological innovation vaccines are the mission of Ab&B Bio
Contact
E-mail:info@abbbio.com.cn
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
